Literature DB >> 12498906

Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers.

Simon Lowes1, Megan E Cavet, Nicholas L Simmons.   

Abstract

Caco-2 epithelial layers were used as a model to re-evaluate the mechanism(s) by which intestinal digoxin absorption is limited by its active secretion back into the lumen. It is widely recognised that intestinal secretion of digoxin is mediated by the ATP-binding cassette (ABC) transporter Multidrug Resistance 1, MDR1. In MDR1-transfected Madin-Darby canine kidney, MDCKII, cell monolayers, digoxin secretion was reduced by the MDR1 inhibitor cyclosporin A, whereas no inhibition was seen in the presence of MK-571, 3-([(3-(2-[7-chloro-2-quinolinyl]ethyl)phenyl]-[(3-dimethylamino-3-oxoprphyl)-thio)-methyl]-thio) propanoic acid, a Multidrug Related Protein (MRP) inhibitor. In contrast, digoxin secretion by Caco-2 epithelia was significantly inhibited by both cyclosporin A and MK-571, suggesting that an additional non-MDR1 component may contribute to this transport. Since digoxin secretion by MRP2-transfected MDCKII monolayers was increased by only 1.2-fold relative to controls, it is likely that the contribution of MRP2 to digoxin secretion by Caco-2 cells is negligible. An additional MK-571-sensitive secretory pathway for digoxin, together with MDR1, is likely to mediate digoxin secretion in Caco-2 epithelia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12498906     DOI: 10.1016/s0014-2999(02)02764-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.

Authors:  Joseph D Ma; Shirley M Tsunoda; Joseph S Bertino; Meghana Trivedi; Keola K Beale; Anne N Nafziger
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

2.  Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Authors:  Joe Bentz; Michael P O'Connor; Dallas Bednarczyk; Joann Coleman; Caroline Lee; Johan Palm; Y Anne Pak; Elke S Perloff; Eric Reyner; Praveen Balimane; Marie Brännström; Xiaoyan Chu; Christoph Funk; Ailan Guo; Imad Hanna; Krisztina Herédi-Szabó; Kate Hillgren; Libin Li; Evelyn Hollnack-Pusch; Masoud Jamei; Xuena Lin; Andrew K Mason; Sibylle Neuhoff; Aarti Patel; Lalitha Podila; Emile Plise; Ganesh Rajaraman; Laurent Salphati; Eric Sands; Mitchell E Taub; Jan-Shiang Taur; Dietmar Weitz; Heleen M Wortelboer; Cindy Q Xia; Guangqing Xiao; Jocelyn Yabut; Tetsuo Yamagata; Lei Zhang; Harma Ellens
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

3.  Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.

Authors:  Kari T Kivistö; Jörg Zukunft; Ute Hofmann; Mikko Niemi; Sabine Rekersbrink; Swetlana Schneider; Gerd Luippold; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

4.  Case Study 8: Status of the Structural Mass Action Kinetic Model of P-gp-Mediated Transport Through Confluent Cell Monolayers.

Authors:  Joe Bentz; Harma Ellens
Journal:  Methods Mol Biol       Date:  2021

5.  The Effects of Pregnenolone 16α-Carbonitrile Dosing on Digoxin Pharmacokinetics and Intestinal Absorption in the Rat.

Authors:  Simon Lowes; Iain S Haslam; Britt-Marie Fihn; Constanze Hilgendorf; Johan E Karlsson; Nicholas L Simmons; Anna-Lena Ungell
Journal:  Pharmaceutics       Date:  2010-03-15       Impact factor: 6.321

6.  Transport of organic anions and cations in murine embryonic kidney development and in serially-reaggregated engineered kidneys.

Authors:  Melanie L Lawrence; C-Hong Chang; Jamie A Davies
Journal:  Sci Rep       Date:  2015-03-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.